Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Reynolds

Showing results (51-60 of 1,272) with videos related to

Pageof 128
Sort By:
The International Journal of Neuropsychopharmacology|July 12, 2021
The Etiology of Metabolic Disturbances in Schizophrenia: Drugs, Genes, and EnvironmentGavin P Reynolds
Journal of Psychopharmacology (Oxford, England)|January 1, 1997
What is an atypical antipsychotic?G P Reynolds
Building Operating Management|June 10, 1980
Life safety codes: over-regulated or over-designed?K P Reynolds
Expert Opinion on Pharmacotherapy|March 16, 2001
The new antipsychotics--some pharmacological aspects of their problems and potentialG P Reynolds
Current Oncology Reports|December 21, 2000
Differentiating agents in pediatric malignancies: retinoids in neuroblastomaC P Reynolds
American Journal of Public Health|June 10, 2000
Dr Louis T. Wright and the NAACP: pioneers in hospital racial integrationP P Reynolds
Drug Discovery Today|November 13, 2007
The impact of pharmacogenetics on the development and use of antipsychotic drugsGavin P Reynolds
Psychiatry Investigation|March 8, 2012
The pharmacogenetics of symptom response to antipsychotic drugsGavin P Reynolds
American Family Physician|February 16, 2006
Dysmorphic findings in persons with fragile X syndromeFrank P Reynolds
Biochemical Society Transactions|February 1, 1996
Dopamine receptors and schizophreniaG P Reynolds
Pageof 128

Showing results (51-60 of 1,272) with videos related to

Sort By:
Pageof 128
The International Journal of Neuropsychopharmacology|July 12, 2021
The Etiology of Metabolic Disturbances in Schizophrenia: Drugs, Genes, and EnvironmentGavin P Reynolds
Journal of Psychopharmacology (Oxford, England)|January 1, 1997
What is an atypical antipsychotic?G P Reynolds
Building Operating Management|June 10, 1980
Life safety codes: over-regulated or over-designed?K P Reynolds
Expert Opinion on Pharmacotherapy|March 16, 2001
The new antipsychotics--some pharmacological aspects of their problems and potentialG P Reynolds
Current Oncology Reports|December 21, 2000
Differentiating agents in pediatric malignancies: retinoids in neuroblastomaC P Reynolds
American Journal of Public Health|June 10, 2000
Dr Louis T. Wright and the NAACP: pioneers in hospital racial integrationP P Reynolds
Drug Discovery Today|November 13, 2007
The impact of pharmacogenetics on the development and use of antipsychotic drugsGavin P Reynolds
Psychiatry Investigation|March 8, 2012
The pharmacogenetics of symptom response to antipsychotic drugsGavin P Reynolds
American Family Physician|February 16, 2006
Dysmorphic findings in persons with fragile X syndromeFrank P Reynolds
Biochemical Society Transactions|February 1, 1996
Dopamine receptors and schizophreniaG P Reynolds
Pageof 128